Protein post-translational modifications and misfolding: New concepts in heart failure

Proteomics - Clinical Applications

Volumn 8, Issue 7-8, 2014, Pages 534-542

  del Monte, Federica ^a   Agnetti, Giulio ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Heart failure; Post translational modifications; Pre amyloid oligomers

Indexed keywords

ALPHA CRYSTALLIN; AMYLOID; CYSTATIN C; DESMIN; GELSOLIN; OLIGOMER; PREAMYLOID OLIGOMER; UNCLASSIFIED DRUG;

CARDIOTOXICITY; HEART AMYLOIDOSIS; HEART FAILURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN UNFOLDING; PROTEOMICS; REVIEW; ANIMAL; CHEMISTRY; METABOLISM; PROTEINOSIS;

AMYLOID; ANIMALS; HEART FAILURE; HUMANS; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN FOLDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS;

EID: 84906065619     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400037     Document Type: Review

References (73)

1. Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J. et al., Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127, e6-e245.
2. McMurray, J. J., Petrie, M. C., Murdoch, D. R., Davie, A. P., Clinical epidemiology of heart failure: public and private health burden. Eur. Heart J. 1998, 19 Suppl P, P9-16.
3. Prince, M., Prina, M., Guerchet, M., World Alzheimer Report, Alzheimer's Disease International (ADI), London 2013.
4. Gianni, D., Li, A., Tesco, G., McKay, K. M. et al., Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. Circulation 2010, 121, 1216-1226.
5. Campion, D., Dumanchin, C., Hannequin, D., Dubois, B. et al., Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 1999, 65, 664-670.
6. Li, D., Parks, S. B., Kushner, J. D., Nauman, D. et al., Mutations of presenilin genes in dilated cardiomyopathy and heart failure. Am. J. Hum. Genet. 2006, 79, 1030-1039.
7. Agnetti, G., Husberg, C., van Eyk, J. E., Divide and conquer: the application of organelle proteomics to heart failure. Circ. Res. 2011, 108, 512-526.
8. Agnetti, G., Halperin, V. L., Kirk, J. A., Chakir, K. et al., Desmin modifications associate with amyloid-like oligomers deposition in heart failure. Cardiovasc. Res. 2014, 102, 24-34.
9. Pappolla, M. A., Bryant-Thomas, T. K., Herbert, D., Pacheco, J. et al., Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003, 61, 199-205.
10. Razay, G., Vreugdenhil, A., Wilcock, G., The metabolic syndrome and Alzheimer disease. Arch. Neurol. 2007, 64, 93-96.
11. Neubauer, S., The failing heart-an engine out of fuel. N. Engl. J. Med. 2007, 356, 1140-1151.
12. Sanbe, A., Osinska, H., Saffitz, J. E., Glabe, C. G. et al., Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc. Natl. Acad. Sci. USA 2004, 101, 10132-10136.
13. Despa, S., Margulies, K. B., Chen, L., Knowlton, A. A. et al., Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and rats. Circ. Res. 2012, 110, 598-608.
14. Willis, M. S., Patterson, C., Proteotoxicity and cardiac dysfunction-Alzheimer's disease of the heart? N. Engl. J. Med. 2013, 368, 455-464.
15. Katzman, R., Terry, R., DeTeresa, R., Brown, T. et al., Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 1988, 23, 138-144.
16. Rochet, J. C., Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev. Mol. Med. 2007, 9, 1-34.
17. Tyedmers, J., Mogk, A., Bukau, B., Cellular strategies for controlling protein aggregation. Nat. Rev. Mol. Cell Biol. 2010, 11, 777-788.
18. Lefebvre, T., Guinez, C., Dehennaut, V., Beseme-Dekeyser, O. et al., Does O-GlcNAc play a role in neurodegenerative diseases? Expert Rev. Proteomics 2005, 2, 265-275.
19. Nilsson, M. R., in: Sipe, J. D. (Ed.), Amyloid Proteins, the Beta Sheet Conformation and Disease, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 2005, pp. 81.
20. Abedini, A., Gupta, R., Marek, P., Meng, F. et al., in: Ramirez-Alvarado, M., Kelly, J. W., Dobson, C. M. (Eds), Protein Misfolding Diseases: Current and Emerging Principles and Therapies, John Wiley and Sons, Inc 2010, pp. 131-144.
21. Gorza, L., del Monte, F., Protein unfolding in cardiomyopathies. Heart Fail. Clin. 2005, 1, 237-250.
22. Mannini, B., Cascella, R., Zampagni, M., van Waarde-Verhagen, M. et al., Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers. Proc. Natl. Acad. Sci. USA 2012, 109, 12479-12484.
23. Sandri, M., Robbins, J., Proteotoxicity: an underappreciated pathology in cardiac disease. J. Mol. Cell. Cardiol. 2013, 71, 3-10.
24. Wang, X., Robbins, J., Proteasomal and lysosomal protein degradation and heart disease. J. Mol. Cell. Cardiol. 2013, 71, 16-24.
25. Chiti, F., Dobson, C. M., Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75, 333-366.
26. Walter, J., Haass, C., Post-translational modifications of amyloid precursor protein: ectodomain phosphorylation and sulfation. Methods Mol. Med. 2000, 32, 149-68.
27. Georgopoulou, N., McLaughlin, M., McFarlane, I., Breen, K. C., The role of post-translational modification in beta-amyloid precursor protein processing. Biochem. Soc. Symp. 2001, 67, 23-36.
28. Haass, C., Selkoe, D. J., Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8, 101-112.
29. Tay, W. M., Bryant, J. G., Martin, P. K., Nix, A. J. et al., A mass spectrometric approach for characterization of amyloid-beta aggregates and identification of their post-translational modifications. Biochemistry 2012, 51, 3759-3766.
30. Diguet, N., Mallat, Y., Ladouce, R., Clodic, G. et al., Muscle creatine kinase deficiency triggers both actin depolymerization and desmin disorganization by advanced glycation end products in dilated cardiomyopathy. J. Biol. Chem. 2011, 286, 35007-35019.
31. Robinson, N. E., Robinson, A. B., Molecular clocks. Proc. Natl. Acad. Sci. USA 2001, 98, 944-949.
32. Muller, U. C., Zheng, H., Physiological functions of APP family proteins. Cold Spring Harb. Perspect. Med. 2012, 2, 1-17.
33. Hein, S., Kostin, S., Heling, A., Maeno, Y., Schaper, J., The role of the cytoskeleton in heart failure. Cardiovasc. Res. 2000, 45, 273-278.
34. Snider, N. T., Omary, M. B., Post-translational modifications of intermediate filament proteins: mechanisms and functions. Nat. Rev. Mol. Cell Biol. 2014, 15, 163-177.
35. Baird, F. J., Bennett, C. L., Microtubule defects & neurodegeneration. J. Genet. Syndr. Gene Ther. 2013, 4, 203-217.
36. Chinnakkannu, P., Samanna, V., Cheng, G., Ablonczy, Z. et al., Site-specific microtubule-associated protein 4 dephosphorylation causes microtubule network densification in pressure overload cardiac hypertrophy. J. Biol. Chem. 2010, 285, 21837-21848.
37. Maury, C. P., Gelsolin-related amyloidosis. Identification of the amyloid protein in Finnish hereditary amyloidosis as a fragment of variant gelsolin. J. Clin. Invest. 1991, 87, 1195-1199.
38. Clemen, C. S., Herrmann, H., Strelkov, S. V., Schroder, R., Desminopathies: pathology and mechanisms. Acta. Neuropathol. 2013, 125, 47-75.
39. Sanbe, A., Osinska, H., Saffitz, J. E., Glabe, C. G. et al., Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc. Natl. Acad. Sci. USA 2004, 101, 10132-10136.
40. Agnetti, G., Bezstarosti, K., Dekkers, D. H., Verhoeven, A. J. et al., Proteomic profiling of endothelin-1-stimulated hypertrophic cardiomyocytes reveals the increase of four different desmin species and alpha-B-crystallin. Biochim. Biophys. Acta 2008, 1784, 1068-1076.
41. Sipe, J. D., Benson, M. D., Buxbaum, J. N., Ikeda, S. et al., Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010, 17, 101-104.
42. Glabe, C. G., Structural classification of toxic amyloid oligomers. J. Biol. Chem. 2008, 283, 29639-29643.
43. Roberts, B. E., Duennwald, M. L., Wang, H., Chung, C. et al., A synergistic small-molecule combination directly eradicates diverse prion strain structures. Nat. Chem. Biol. 2009, 5, 936-946.
44. Maloyan, A., Gulick, J., Glabe, C. G., Kayed, R., Robbins, J., Exercise reverses preamyloid oligomer and prolongs survival in {alpha}B-crystallin-based desmin-related cardiomyopathy. Proc. Natl. Acad. Sci. USA 2007, 104, 5995-6000.
45. Abedini, A., Schmidt, A. M., Mechanisms of islet amyloidosis toxicity in type 2 diabetes. FEBS Lett. 2013, 587, 1119-1127.
46. Demuro, A., Parker, I., Stutzmann, G. E., Calcium signaling and amyloid toxicity in Alzheimer disease. J. Biol. Chem. 2010, 285, 12463-12468.
47. Cerf, E., Sarroukh, R., Tamamizu-Kato, S., Breydo, L. et al., Antiparallel beta-sheet: a signature structure of the oligomeric amyloid beta-peptide. Biochem. J. 2009, 421, 415-423.
48. Wolfe, M. S., When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007, 8, 136-140.
49. Willis, M. S., Bevilacqua, A., Pulinilkunnil, T., Kienesberger, P. et al., The role of ubiquitin ligases in cardiac disease. J. Mol. Cell. Cardiol. 2013, 71, 43-53.
50. Hart, G. W., Ball, L. E., Post-translational modifications: a major focus for the future of proteomics. Mol. Cell. Proteomics 2013, 12, 3443.
51. Zhang, P., Kirk, J. A., Ji, W., dos Remedios, C. G. et al., Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. Circulation 2012, 126, 1828-1837.
52. Bodiga, V. L., Eda, S. R., Bodiga, S., Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail. Rev. 2014, 19, 49-63.
53. Lopez-Clavijo, A. F., Duque-Daza, C. A., O'Connor, P. B., Tandem mass spectrometry for the study of glyoxal-derived advanced glycation end-products (AGEs) in peptides. Rapid Commun. Mass Spectrom. 2014, 28, 25-32.
54. Willemsen, S., Hartog, J. W., van Veldhuisen, D. J., van der Meer, P. et al., The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. Am. Heart J. 2012, 164, 742-749.e3.
55. Sylvestersen, K. B., Young, C., Nielsen, M. L., Advances in characterizing ubiquitylation sites by mass spectrometry. Curr. Opin. Chem. Biol. 2013, 17, 49-58.
56. Jones, J., Wu, K., Yang, Y., Guerrero, C. et al., A targeted proteomic analysis of the ubiquitin-like modifier nedd8 and associated proteins. J. Proteome Res. 2008, 7, 1274-1287.
57. Koyano, F., Okatsu, K., Kosako, H., Tamura, Y. et al., Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 2014, 510, 162-166.
58. Marx, V., Targeted proteomics. Nat. Methods 2013, 10, 19-22.
59. Brinkmalm, G., Portelius, E., Ohrfelt, A., Mattsson, N. et al., An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid. J. Mass Spectrom. 2012, 47, 591-603.
60. Pan, J., Han, J., Borchers, C. H., Konermann, L., Structure and dynamics of small soluble Abeta(1-40) oligomers studied by top-down hydrogen exchange mass spectrometry. Biochemistry 2012, 51, 3694-3703.
61. Patterson, C., Search and destroy: the role of protein quality control in maintaining cardiac function. J. Mol. Cell. Cardiol. 2006, 40, 438-441.
62. Hard, T., Lendel, C., Inhibition of amyloid formation. J. Mol. Biol. 2012, 421, 441-465.
63. Ho, L., Pasinetti, G. M., Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding. Expert Rev. Proteomics 2010, 7, 579-589.
64. Bulawa, C. E., Connelly, S., Devit, M., Wang, L. et al., Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl. Acad. Sci. USA 2012, 109, 9629-9634.
65. Castano, A., Helmke, S., Alvarez, J., Delisle, S., Maurer, M. S., Diflunisal for ATTR cardiac amyloidosis. Congest. Heart Fail. 2012, 18, 315-319.
66. Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y. et al., Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013, 310, 2658-2667.
67. Kastritis, E., Wechalekar, A. D., Dimopoulos, M. A., Merlini, G. et al., Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J. Clin. Oncol. 2010, 28, 1031-1037.
68. Venner, C. P., Lane, T., Foard, D., Rannigan, L. et al., Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012, 119, 4387-4390.
69. Mikhael, J. R., Schuster, S. R., Jimenez-Zepeda, V. H., Bello, N. et al., Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012, 119, 4391-4394.
70. de Waard, M. C., van der Velden, J., Bito, V., Ozdemir, S. et al., Early exercise training normalizes myofilament function and attenuates left ventricular pump dysfunction in mice with a large myocardial infarction. Circ. Res. 2007, 100, 1079-1088.
71. Um, H. S., Kang, E. B., Leem, Y. H., Cho, I. H. et al., Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. Int. J. Mol. Med. 2008, 22, 529-539.
72. Downing, J., Balady, G. J., The role of exercise training in heart failure. J. Am. Coll. Cardiol. 2011, 58, 561-569.
73. Bhuiyan, M. S., Pattison, J. S., Osinska, H., James, J. et al., Enhanced autophagy ameliorates cardiac proteinopathy. J. Clin. Invest. 2013, 123, 5284-5297.